Compare Stocks: CPIX, FENC, ENTA, and BIOA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOA BioAge Labs	$8.30 +2.6%	$13.02	$4.90 ▼ $25.95	$379.00M	0.94	695,409 shs	144,388 shs
CPIX Cumberland Pharmaceuticals	$7.67 +1.0%	$7.31	$1.85 ▼ $9.28	$114.69M	0.13	421,382 shs	14,069 shs
ENTA Enanta Pharmaceuticals	$12.26 +1.3%	$13.25	$7.05 ▼ $17.15	$354.28M	0.93	203,259 shs	28,315 shs
FENC Adherex Technologies	$10.97 +0.5%	$11.14	$5.65 ▼ $13.25	$382.33M	1.1	210,620 shs	25,519 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOA BioAge Labs	+0.37%	-4.60%	-14.66%	-63.75%	+65.10%
CPIX Cumberland Pharmaceuticals	+3.69%	+13.28%	-0.78%	+30.19%	+140.95%
ENTA Enanta Pharmaceuticals	-0.74%	-7.70%	-10.10%	-13.87%	+58.51%
FENC Adherex Technologies	+2.73%	+1.77%	-3.37%	+5.92%	+25.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOA BioAge Labs	$8.30 +2.6%	$13.02	$4.90 ▼ $25.95	$379.00M	0.94	695,409 shs	144,388 shs
CPIX Cumberland Pharmaceuticals	$7.67 +1.0%	$7.31	$1.85 ▼ $9.28	$114.69M	0.13	421,382 shs	14,069 shs
ENTA Enanta Pharmaceuticals	$12.26 +1.3%	$13.25	$7.05 ▼ $17.15	$354.28M	0.93	203,259 shs	28,315 shs
FENC Adherex Technologies	$10.97 +0.5%	$11.14	$5.65 ▼ $13.25	$382.33M	1.1	210,620 shs	25,519 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOA BioAge Labs	+0.37%	-4.60%	-14.66%	-63.75%	+65.10%
CPIX Cumberland Pharmaceuticals	+3.69%	+13.28%	-0.78%	+30.19%	+140.95%
ENTA Enanta Pharmaceuticals	-0.74%	-7.70%	-10.10%	-13.87%	+58.51%
FENC Adherex Technologies	+2.73%	+1.77%	-3.37%	+5.92%	+25.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIOA BioAge Labs	2.71	Moderate Buy	$36.57	340.41% Upside
CPIX Cumberland Pharmaceuticals	1.00	Sell	N/A	N/A
ENTA Enanta Pharmaceuticals	2.67	Moderate Buy	$21.00	71.25% Upside
FENC Adherex Technologies	2.50	Moderate Buy	$17.00	54.97% Upside

Current Analyst Ratings Breakdown

Latest CPIX, FENC, ENTA, and BIOA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	BIOA BioAge Labs	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/9/2026	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
9/8/2026	BIOA BioAge Labs	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
8/12/2026	FENC Adherex Technologies	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00 ➝ $18.00
8/12/2026	FENC Adherex Technologies	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $16.00
8/3/2026	BIOA BioAge Labs	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
7/31/2026	BIOA BioAge Labs	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
7/31/2026	BIOA BioAge Labs	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
7/31/2026	BIOA BioAge Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$50.00 ➝ $35.00
7/21/2026	BIOA BioAge Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ENTA Enanta Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIOA BioAge Labs	$8.99M	42.40	N/A	N/A	$7.59 per share	1.09
CPIX Cumberland Pharmaceuticals	$44.52M	2.58	$0.38 per share	19.96	$1.64 per share	4.68
ENTA Enanta Pharmaceuticals	$65.26M	5.47	N/A	N/A	$3.03 per share	4.05
FENC Adherex Technologies	$44.64M	8.62	N/A	N/A	$1.04 per share	10.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIOA BioAge Labs	-$80.61M	-$2.38	N/A	N/A	N/A	-912.26%	-28.99%	-27.09%	N/A
CPIX Cumberland Pharmaceuticals	-$2.84M	-$0.71	N/A	N/A	N/A	-34.40%	-28.81%	-9.25%	11/3/2026 (Estimated)
ENTA Enanta Pharmaceuticals	-$81.89M	-$2.41	N/A	N/A	N/A	-96.89%	-61.84%	-20.70%	11/16/2026 (Estimated)
FENC Adherex Technologies	-$9.74M	-$0.13	N/A	11.31	N/A	-6.09%	-5.71%	-2.37%	11/12/2026 (Estimated)

Latest CPIX, FENC, ENTA, and BIOA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FENC Adherex Technologies	$0.02	$0.05	+$0.03	$0.05	$16.21 million	$17.87 million
8/10/2026	Q3 2026	ENTA Enanta Pharmaceuticals	-$0.5095	-$0.67	-$0.1605	-$0.67	$16.76 million	$14.36 million
8/5/2026	Q2 2026	BIOA BioAge Labs	-$0.65	-$0.58	+$0.07	-$0.58	N/A	$2.45 million
8/4/2026	Q2 2026	CPIX Cumberland Pharmaceuticals	-$0.13	-$0.20	-$0.07	-$0.29	$8.50 million	$0.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIOA BioAge Labs	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A

Latest CPIX, FENC, ENTA, and BIOA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/13/2026	CPIX Cumberland Pharmaceuticals		$1.50			7/23/2026	7/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIOA BioAge Labs	N/A	17.19	17.19
CPIX Cumberland Pharmaceuticals	N/A	0.96	0.96
ENTA Enanta Pharmaceuticals	N/A	3.76	3.76
FENC Adherex Technologies	N/A	5.85	5.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIOA BioAge Labs	N/A
CPIX Cumberland Pharmaceuticals	15.51%
ENTA Enanta Pharmaceuticals	94.99%
FENC Adherex Technologies	55.51%

Insider Ownership

Company	Insider Ownership
BIOA BioAge Labs	17.55%
CPIX Cumberland Pharmaceuticals	42.07%
ENTA Enanta Pharmaceuticals	11.48%
FENC Adherex Technologies	10.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIOA BioAge Labs	62	45.90 million	37.84 million	N/A
CPIX Cumberland Pharmaceuticals	93	14.98 million	8.68 million	Optionable
ENTA Enanta Pharmaceuticals	120	29.13 million	25.78 million	Optionable
FENC Adherex Technologies	35	35.06 million	31.30 million	Optionable

CPIX, FENC, ENTA, and BIOA Headlines

Recent News About These Companies

Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026

September 17, 2026 | globenewswire.com

What is HC Wainwright's Estimate for FENC Q3 Earnings?

September 12, 2026 | americanbankingnews.com

Adherex Technologies (NASDAQ:FENC) Earns Buy Rating from HC Wainwright

September 11, 2026 | americanbankingnews.com

Equities Analysts Set Expectations for FENC Q3 Earnings

September 10, 2026 | marketbeat.com

Adherex Technologies' (FENC) "Buy" Rating Reiterated at HC Wainwright

September 9, 2026 | marketbeat.com

Pierre Sargis Sayad Sells 12,000 Shares of Adherex Technologies (NASDAQ:FENC) Stock

September 1, 2026 | insidertrades.com

Adherex Technologies (NASDAQ:FENC) Insider Pierre Sargis Sayad Sells 12,000 Shares of Stock

August 31, 2026 | marketbeat.com

Adherex Technologies (NASDAQ:FENC) CFO Sells 75,000 Shares

August 29, 2026 | insidertrades.com

Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Rating of "Moderate Buy" from Analysts

August 29, 2026 | marketbeat.com

Adherex Technologies (NASDAQ:FENC) CFO Sells $883,500.00 in Stock

August 28, 2026 | marketbeat.com

Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?

August 12, 2026 | zacks.com

Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates

August 11, 2026 | zacks.com

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

August 5, 2026 | globenewswire.com

Is the Options Market Predicting a Spike in Adherex Technologies Stock?

July 6, 2026 | zacks.com

Fennec Announces Results of Annual Meeting

June 10, 2026 | globenewswire.com

Adherex Technologies' PEDMARK push targets larger AYA market after record quarter

May 23, 2026 | msn.com

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

May 21, 2026 | globenewswire.com

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026 | globenewswire.com

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2026 Earnings Call Transcript

May 15, 2026 | insidermonkey.com

Do options traders know something about Adherex Technologies stock we don't?

May 14, 2026 | msn.com

Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript

May 14, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CPIX, FENC, ENTA, and BIOA Company Descriptions

BioAge Labs NASDAQ:BIOA

$8.30 +0.21 (+2.65%)

As of 11:17 AM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Cumberland Pharmaceuticals NASDAQ:CPIX

$7.67 +0.08 (+1.03%)

As of 11:16 AM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Enanta Pharmaceuticals NASDAQ:ENTA

$12.26 +0.15 (+1.26%)

As of 11:17 AM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Adherex Technologies NASDAQ:FENC

$10.97 +0.06 (+0.55%)

As of 11:16 AM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPIX, FENC, ENTA, and BIOA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPIX, FENC, ENTA, and BIOA Earnings

Compare Dividends

Latest CPIX, FENC, ENTA, and BIOA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPIX, FENC, ENTA, and BIOA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CPIX, FENC, ENTA, and BIOA Company Descriptions

BioAge Labs NASDAQ:BIOA

Cumberland Pharmaceuticals NASDAQ:CPIX

Enanta Pharmaceuticals NASDAQ:ENTA

Adherex Technologies NASDAQ:FENC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools